18F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma
18F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma
复制标题
基于 18F-FDG PET/CT 的脾脏与肝脏比率与转移性黑色素瘤患者伊匹单抗的临床结果相关
DOI：
10.1186/s40644-020-00313-2
复制
发表时间：
2020
期刊：
影响因子：
4.9
通讯作者：
R. Hicks
中科院分区：
文献类型：
--
作者：
Annie Wong;J. Callahan;M. Keyaerts;B. Neyns;J. Mangana;S. Aberle;A. Herschtal;S. Fullerton;D. Milne;A. Iravani;G. McArthur;R. Hicks
免疫检查点阻断剂如易普利姆玛和抗PD 1单克隆抗体显著改善了晚期黑色素瘤的生存率。迫切需要生物标志物，因为尽管存在治疗相关毒性，但大多数患者没有反应。我们分析了治疗前18F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（FDG PET/CT）参数，以评估其与患者结局的相关性。这项回顾性研究评价了接受伊匹单抗或抗PD 1治疗的晚期黑色素瘤患者的发现队列中的治疗前FDG PET/CT扫描。评估治疗前扫描的最大肿瘤标准化摄取值（SUVmax）、代谢肿瘤体积（MTV）和脾肝比（SLR）。采用单变量和多变量分析对无进展生存期（PFS）和总生存期（OS）进行表征和建模。在一个独立队列中验证了SLR和OS的相关性。分析来自发现队列的患者的血液参数和储存的血清，以研究与SLR的生物学相关性。在发现队列中的90名可评估患者中：50名接受伊匹单抗单药治疗，20名接受抗PD 1单药治疗，20名患者在疾病进展后接受伊匹单抗治疗，随后接受抗PD 1治疗。对于接受伊匹单抗治疗的患者，高SLR > 1.1与不良PFS相关（中位数1 vs 3个月; HR 3.14，p = 0.008）。高SLR与伊匹单抗治疗后的OS差相关（中位数1 vs 21个月; HR 5.83，p = 0.0001）;以及伊匹单抗或抗PD 1一线免疫治疗后的OS差相关（中位数1 vs 14个月; HR 3.92，p = 0.003）。在110例患者的独立队列中验证了伊匹单抗治疗后高SLR和OS差的相关性（中位数2.3个月vs 11.9个月，HR 3.74）。在独立于分期、LDH、绝对淋巴细胞计数和MTV的多变量模型中，SLR与OS较差相关。治疗前脾肝比（SLR）> 1.1与伊匹单抗治疗晚期黑色素瘤后的不良结局相关。该参数保证了前瞻性评价。
Immune checkpoint blockade such as ipilimumab and anti-PD1 monoclonal antibodies have significantly improved survival in advanced melanoma. Biomarkers are urgently needed as a majority of patients do not respond, despite treatment-related toxicities. We analysed pre-treatment 18F-fluorodeoxyglucose positron emission tomography/computerised tomography (FDG PET/CT) parameters to assess its correlation with patient outcome. This retrospective study evaluated pre-treatment FDG PET/CT scans in a discovery cohort of patients with advanced melanoma treated with ipilimumab or anti-PD1. Pre-treatment scans were assessed for maximum tumoral standardised uptake value (SUVmax), metabolic tumour volume (MTV) and spleen to liver ratio (SLR). Progression-free survival (PFS) and overall survival (OS) were characterised and modelled using univariable and multivariable analyses. Correlation of SLR and OS was validated in an independent cohort. Blood parameters and stored sera of patients from the discovery cohort was analysed to investigate biological correlates with SLR. Of the 90 evaluable patients in the discovery cohort: 50 received ipilimumab monotherapy, 20 received anti-PD1 monotherapy, and 20 patients received ipilimumab followed by anti-PD1 upon disease progression. High SLR > 1.1 was associated with poor PFS (median 1 vs 3 months; HR 3.14, p = 0.008) for patients treated with ipilimumab. High SLR was associated with poor OS after ipilimumab (median 1 vs 21 months; HR 5.83, p = 0.0001); as well as poor OS after first line immunotherapy of either ipilimumab or anti-PD1 (median 1 vs 14 months; HR 3.92, p = 0.003). The association of high SLR and poor OS after ipilimumab was validated in an independent cohort of 110 patients (median 2.3 months versus 11.9 months, HR 3.74). SLR was associated with poor OS in a multi-variable model independent of stage, LDH, absolute lymphocyte count and MTV. Pre-treatment Spleen to liver ratio (SLR) > 1.1 was associated with poor outcome after ipilimumab in advanced melanoma. This parameter warrants prospective evaluation.
影响因子：
45.3
作者：
Daud, Adil I.;Wolchok, Jedd D.;Hamid, Omid
通讯作者：
Hamid, Omid
DOI：
10.1056/nejmoa1406498
发表时间：
2014-12-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Snyder A;Makarov V;Merghoub T;Yuan J;Zaretsky JM;Desrichard A;Walsh LA;Postow MA;Wong P;Ho TS;Hollmann TJ;Bruggeman C;Kannan K;Li Y;Elipenahli C;Liu C;Harbison CT;Wang L;Ribas A;Wolchok JD;Chan TA
通讯作者：
Chan TA
影响因子：
19.7
作者：
ZASADNY, KR;WAHL, RL
通讯作者：
WAHL, RL